Skip to main content

Table 1 Outcome of triage by HPV test (n = 564)

From: 5-type HPV mRNA versus 14-type HPV DNA test: test performance, over-diagnosis and overtreatment in triage of women with minor cervical lesions

 

DNA

5-type-mRNA

N = 564

% (95 % CI)

N = 564

% (95 % CI)

Back to screening

399

70.7 (66.9–74.5)

459

81.4 (78.2–84.6)*

Met for biopsy

105

18.6 (15.4–21.8)

77

13.7 (10.9–16.5)

Scheduled, not met for biopsy

36

6.4 (4.4–8.4)

15

2.7 (1.4–4.0)*

Incomplete follow-up

24

4.3 (2.6–6.0)

13

2.3 (1.1–3.5)

  1. *p < 0.05
  2. Triage repeat cytology and HPV test 3–18 months after index ASC-US/LSIL cytology
  3. DNA HPV DNA test (Cobas 4800)
  4. 5-type-mRNA HPV mRNA test (PreTect HPV-Proofer)